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Abstract- We describe the first case series (n = 6) of using chlordiazepoxide to accomplish a rapid, 
well-tolerated withdrawal from alprazolam. After abruptly discontinuing alprazolam, we substi- 
tuted a 50-mg dose of chlordiazepoxide for each I mg of alprazolam (except for one elderly patient 
where we substituted 25 mg) and gave additional chlordiazepoxide doses (25-50 mg every 4-6 hours) 
as neededfor the first l-2 days of hospitalization. With this approach, the mean ‘substitution ra- 
tio" of ChIordiazepoxide to alprazolam was 86 to I. We then tapered chlordiazepoxide by an aver- 
age of 10% each day over a 7- to Il-day period according to the symptoms manifested and tolerated 
by individual patients. No seizures or other serious side effects occurred. Incomplete cross- 
dependence, as described elsewhere in the literature, was not observed. The rapidity and familiar- 
ity of the method are advantages for inpatient units, but careful titration of dosage, diagnostic clarity, 
and extended follow-ups are necessary when applying this approach, 
Keywords-alprazolam; chlordiazepoxide; benzodiazepines; substance withdrawal; substance 
dependence. 
INTRODUCTION 
ALPRAZOLAM IS A BENZODIAZEPINE MEDICATION that is 
highly effective and well studied for treating panic dis- 
order (Schweizer, Rickels, Weiss, & Zavodnick, 1993). 
Panic disorder results in significant disability (Mar- 
kowitz, Weissman, Ouellette, Lish, & Klerman, 1989) 
and may increase the risk for suicide (Noyes, 1991). 
Although other therapies are available @elder, 1991), 
alprazolam often works more quickly and has fewer 
side effects and greater patient acceptance (Schweizer 
et al., 1993). Given the benefits of alprazolam and the 
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importance of treating panic disorder, physicians will 
likely continue prescribing it in the near future. 
Alprazolam, like other benzodiazepines, has defi- 
nite abuse liability (American Psychiatric Association, 
1990; Ciraulo & Sarid-Segal, 1991; Juergens, 1991). 
Here, abuse refers to taking alprazolam for its nonmed- 
ical, euphoric effects despite harmful consequences. 
The vast majority of treated patients do not abuse ben- 
zodiazepines (American Psychiatric Association, 1990; 
Woods, Katz, & Winger, 1988). A prior history of sub- 
stance abuse, abusing other substances such as alco- 
hol or opioids, and a family history of alcoholism may 
all increase the risk for benzodiazepine abuse (Ciraulo 
& Sarid-Segal, 1991; Woods et al., 1988). 
Apart from its abuse potential, physical dependence 
on alprazolam develops frequently (Fyer et al., 1987; 
Received August 2, 1993; Accepted March 8, 1994. 
319 
320 M. H. Glosser and K. J. Bro wer 
Rickels, Schweizer, Weiss, & Zavodnick, 1993). Phys- 
ical dependence refers to the appearance of withdrawal 
symptoms upon reducing or discontinuing drug use. 
Physical dependence on alprazolam occurs even with 
controlled use of therapeutic doses. In studies of grad- 
ual alprazolam discontinuation in panic-disordered 
patients, 53-63% of them had moderate to severe with- 
drawal symptoms after taking therapeutic doses for 
3-10 months (Fyer et al., 1987; Rickels et al., 1993). 
Some evidence suggests that withdrawal from alpra- 
zolam may be more difficult than withdrawal from 
some other benzodiazepines, because of its higher po- 
tency and shorter duration of action (Noyes, Garvey, 
Cook, & Suelzer, 1991). Withdrawal symptoms include 
agitation, anxiety, depersonalization and derealization, 
depression, diaphoresis, difficulty concentrating, diz- 
ziness, headaches, increased perceptual acuity for sights 
and sounds, insomnia, light-headedness, loss of appe- 
tite, malaise, muscular pains, nausea, poor coordina- 
tion, restlessness, tachycardia, tremor, and weakness 
(Fyer et al., 1987; Pecknold, Swinson, Kuch, 8~ Lewis, 
1988; Rickels et al., 1993). Symptoms may begin within 
1 day of stopping alprazolam, peak within 3 days to 
2 weeks, and generally subside by 2-4 weeks (American 
Psychiatric Association, 1990; Fyer et al., 1987; Peck- 
nold et al., 1988; Rickels et al., 1993). At worst, seizures, 
delirium, and psychosis can occur during alprazolam 
withdrawal (Browne & Hauge, 1986; Warner, Pea- 
body, Boutros, & Whiteford, 1990; Zipursky, Baker, 
& Zimmer, 1985), so abrupt or rapid discontinuation 
without other pharmacological intervention is clearly 
contraindicated. 
The manufacturer recommends a reduction in al- 
prazolam of not more than 0.5 mg every 3 days. Al- 
though this recommendation provides a maximal rate, 
many patients do not tolerate a taper this rapid, espe- 
cially toward the end of their tapers, and so optimal 
rates of reduction are usually slower. Even if one as- 
sumes the maximal rate, a taper from 6 mg would take 
36 days. Patients and physicians sometimes desire 
more rapid techniques, especially in chemical depen- 
dency treatment settings. 
Substitution strategies make rapid discontinuation 
possible. Typically, alprazolam is discontinued abruptly, 
and a long-acting sedative is substituted to suppress 
harmful withdrawal symptoms, after which the latter 
sedative is tapered completely over l-2 weeks. Pheno- 
barbital (Juergens & Morse, 1988; Ravi, Maany, Burke, 
Dhopesh, & Woody, 1990) and the benzodiazepines, 
clonazepam (Albeck, 1987; Patterson, 1990), diazepam 
(Harrison, Busto, Naranjo, Kaplan, & Sellers, 1984), 
and chlordiazepoxide (Juergens & Morse, 1988), have 
all been used this way. Other classes of medications 
such as carbamazepine(Ries, Roy-Byrne, Ward, Neppe, 
& Cullison, 1989; Schweizer, Rickels, Case, & Green- 
blatt, 1991) and clonidine (Fyer et al., 1988) have been 
used adjunctively to facilitate the rate of alprazolam 
reduction with varying degrees of success. 
After a patient on our unit suffered a seizure dur- 
ing alprazolam reduction without substitution, we de- 
veloped a protocol for chlordiazepoxide substitution 
and taper. We reasoned that chlordiazepoxide had the 
advantage of familiarity on our treatment unit, where 
we regularly employed it to treat alcohol withdrawal. 
METHOD 
Patients 
The sample consisted of consecutively admitted inpa- 
tients to our chemical dependency unit from 1987 to 
1989 whose primary diagnosis was alprazolam depen- 
dence, and who had a history of withdrawal symptoms 
upon discontinuation. During this period, we treated 
six patients for alprazolam withdrawal (Table 1). The 
charts of our six patients were retrospectively reviewed 
for demographics, alprazolam history, diagnoses, and 
hospital course. 
Treatment Procedures 
On admission all patients received complete medical, 
psychiatric, substance use, and laboratory evaluations. 
For treatment of alprazolam withdrawal, a modifica- 
tion of our alcohol detoxification protocol was imple- 
mented. Except for one case, we substituted 50 mg 
of chlordiazepoxide for each 1 mg of alprazolam re- 
ported, and we gave this amount orally as a regular 
divided dosage (3-4 times daily). Our exceptional case 
was an elderly patient (72 years old) for whom we sub- 
stituted 25 mg of chlordiazepoxide for each 1 mg of 
alprazolam. In addition, we gave each patient supple- 
mental doses of chlordiazepoxide by mouth: 25-50 mg 
every 4-6 hours as needed to suppress withdrawal 
symptoms. The next scheduled dose was held if the 
patient was drowsy. If withdrawal symptoms wors- 
ened on the second day, then we allowed an additional 
24-hour period of “as-needed” dosing in addition to the 
regular dosing. The total 24-hour dosage of chlordi- 
azepoxide (regular plus supplemental amounts) needed 
to suppress withdrawal was regarded to be equivalent 
to the patient’s daily alprazolam dosage. We then de- 
creased chlordiazepoxide at an average rate of 10% per 
day (range 7.7%-14.3%). The rate of taper was indi- 
vidualized as determined by each patient’s symptom 
profile. In sum, we took 1-2 days to establish a sub- 
stitution dose, and then tapered the substituted dose 
over the next 7-14 days. 
After the taper was finished, patients were expected 
to complete a 2-week program of chemical dependency 
rehabilitation. We made follow-up observations dur- 





Alprazolam Duration of Chlordiazepoxide Chlordiazepoxide 
Dosea Alprazolam Doseb DurationC Substitution 
Patient (mg/d) (mo) (m9) (days) Ratiod 
1 6.0 (12) 4 300 9 50.00 
2 4.0 72 350 15 87.50 
3 3.0 48 195 15 65.00 
4 4.0 72 225 10 56.25 
5 2.0 (10) 60 350 9 175.00 
6 5.0 48 400 9 80.00 
aAlprazolam dosage on admission. For cases 1 and 5, value in parentheses is dose from which outpatient taper began prior to hospitalization. 
bTotal 24-hr dosage needed to suppress withdrawal symptoms. 
‘Total days of chlordiazepoxide administration, including substitution and taper. 
dChlordiazepoxide dosage in column 4 divided by alprazolam dosage in column 2. 
RESULTS 
The mean age of our patients was 44.8 years (range 
23-72), and five patients were female. The primary in- 
dications for initially prescribing alprazolam were 
panic disorder in five patients (two of whom had ad- 
ditional admitting diagnoses of either generalized anx- 
iety or social phobia) and generalized anxiety by itself 
in one patient. Discharge diagnoses included alprazo- 
lam dependence (n = 6), major depression (n = l), 
mixed personality disorder (n = l), alcohol dependence 
(n = l), alcohol and cannabis dependence (n = l), and 
bulimia (n = 1). Patients’ daily alprazolam dose at time 
of admission ranged from 2 to 6 mg (M = 4.0 mg), 
and the duration of use ranged from 4 to 72 months 
(M = 52.7) (Table 1). For each patient, we calculated 
the “substitution ratio” of chlordiazepoxide to alpra- 
zolam as the total 24-hour dosage of chlordiazepox- 
ide given before tapering, divided by the admission 
dosage of alprazolam (Table 1). The mean substitution 
ratio was 85.6 (range 50-175). The mean number of 
days on chlordiazepoxide was 11.2 (range 9-15 days), 
and the mean number of days to taper chlordiazepox- 
ide was 9.5 (range 7-13 days). All patients remained 
in treatment for the duration of the taper. 
Discontinuation symptoms during chlordiazepox- 
ide administration included anxiety (n = 6), insomnia 
(n = 4), high blood pressure (n = 4), tachycardia (n = 
3), irritability (n = 2), tremor (n = 2), depersonaliza- 
tion or derealization (n = 2), sweatiness (n = l), and 
aches (n = 2). One panic attack was noticed in one pa- 
tient. After chlordiazepoxide was discontinued, we re- 
corded follow-up observations for the remainder of 
hospitalization. One patient was admitted for detoxi- 
fication only and was discharged without symptoms 
2 days after stopping chlordiazepoxide. Another pa- 
tient was asymptomatic for 5 days but then left against 
medical advice before completing the rehabilitation 
program because of a relationship conflict. The other 
four patients were followed for 12, 14, 15, and 48 days, 
respectively, and received regular discharges. During 
the follow-up periods for the six patients, we observed 
the following symptoms: anxiety (n = 4), insomnia 
(n = 3), high blood pressure (n = 2), tachycardia 
(n = l), irritability (n = l), tremor (n = l), deperson- 
alization or derealization (n = l), and headache (n = 
1). No panic attacks were observed during the follow- 
up period. No seizures, episodes of delirium, or psy- 
chosis occurred in any patient during the entire course 
of observation. 
Two patients (cases 1 and 3) had residual symptoms 
at the time of discharge. One patient continued to have 
decreased sleep (~5 hr/night), and the other com- 
plained of mild anxiety. Both patients had complicating 
psychiatric and medical problems requiring medica- 
tions (major depression, mixed personality disorder, 
sustained hypertension, coronary artery disease, chronic 
obstructive pulmonary disease, irritable bowel syn- 
drome, and fibromyositis). We attributed the two pa- 
tients’ residual symptoms to coexisting diagnoses 
rather than to poorly treated alprazolam withdrawal. 
DISCUSSION 
To our knowledge, this is the first reported case series 
in which chlordiazepoxide was used successfully to 
treat inpatients for physical withdrawal from alpra- 
zolam. Early reports cautioned that incomplete cross- 
dependence between alprazolam and either chlordiaz- 
epoxide or diazepam might result in seizures and 
delirium (Browne & Hauge, 1986; Kantor, 1986; 
Zipursky et al., 1985). None of our patients manifested 
seizures, delirium, or psychosis. None of them left 
treatment during the taper, and all of them completed 
the taper without difficulty. In short, we did not ob- 
serve evidence for a lack of cross-dependence between 
alprazolam and chlordiazepoxide in our six patients. 
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The early reported failures with diazepam (Zipursky 
et al., 1985) and chlordiazepoxide (Kantor, 1986) may 
have resulted from drug interactions, insufficient dos- 
ing, or coexisting diagnoses. We are aware of only 
three cases in the literature in which chlordiazepoxide 
was substituted for treating alprazolam withdrawal 
(Albeck, 1987; Juergens &Morse, 1988; Kantor, 1986). 
In the case reported by Kantor (1986), a dose of 150 mg 
did suppress withdrawal symptoms from a daily 2-mg 
dose of alprazolam, but the authors were then unable 
to taper the chlordiazepoxide because of “severe agi- 
tation and crippling back spasm.” They eventually 
substituted diazepam and tapered it over 19 weeks. A 
diagnosis of major depression and concurrent phen- 
elzine administration may have complicated this case. 
Albeck (1987) substituted 300 mg of chlordiazepoxide 
for a daily consumption of lo-35 mg of alprazolam, 
and the patient remained tremulous with tachycardia, 
high blood pressure, diaphoresis, vomiting, formica- 
tion, and headache. This was an insufficient chlordi- 
azepoxide dosage compared with our cases. Eventually, 
10 mg of clonazepam was substituted successfully, 
which has two to four times the potency of alprazo- 
lam (American Psychiatric Association, 1990; Smith 
& Seymour, 1991). Finally, Juergens and Morse (1988) 
used chlordiazepoxide successfully over a 7-day period 
in a patient who was taking 8 mg of alprazolam, but 
they did not report chlordiazepoxide dosage. 
One milligram of alprazolam is generally considered 
equivalent to 20 or 25 mg of chlordiazepoxide (Amer- 
ican Psychiatric Association, 1990; Smith & Seymour, 
1991). This 20-25 : 1 ratio contrasts with our mean sub- 
stitution ratio of 86: 1, but it is closer to the 100: 1 ra- 
tio published by Harrison et al. (1984). Nevertheless, 
Harrison et al. (1984) recommended substituting di- 
azepam in a loading dose that was 40% of reported 
daily consumption, which amounts to a 40: 1 ratio in 
chlordiazepoxide equivalents. Only 1 of 23 patients in 
their case series was alprazolam-dependent, and the au- 
thors did not specify if that case was successfully 
treated or 1 of the 4 patients who left against medical 
advice within 6 days (Harrison et al., 1984). Smith and 
Seymour (1991) observed that their conversion factors 
(25 : 1 for chlordiazepoxide to alprazolam) might be 
low when treating alprazolam withdrawal. We suspect 
that higher ratios are needed when substituting chlor- 
diazepoxide for alprazolam for the purpose of a rapid 
taper, because steady-state concentrations of chlordi- 
azepoxide are not achieved by the time chlordiazepox- 
ide tapering begins (l-2 days after its substitution). 
Smith and Seymour (1991) argued against “as- 
needed” dosing in order to avoid drug-seeking behav- 
ior by sedative-dependent patients. One could argue 
that the higher ratios required by our patients resulted 
from our responding to drug seeking with “as-needed” 
doses. Although clinicians must guard against inadver- 
tently intoxicating their patients, flexible dosing has 
two important advantages. First, it allows for individ- 
ual differences, and we found a wide range of substi- 
tution ratios (Table 1). Second, patients do not always 
know or reliably report how much alprazolam and 
other sedatives they are taking. Indeed, our patient 
who suffered a seizure when we attempted reduction 
without chlordiazepoxide substitution later told us she 
took twice the daily dosage that she reported on ad- 
mission. Providing nursing staff with the discretion to 
administer “as-needed” doses allows for necessary, up- 
ward adjustment of dosing in a timely fashion. Doses 
were withheld if patients showed signs of toxicity such 
as drowsiness, ataxia, slurred speech, double vision, 
and dizziness. Thus, our procedure prevented both 
over- and undermedication problems, as we carefully 
titrated the dosage according to individual need. 
We were hesitant to employ the higher (50: 1) sub- 
stitution ratio of chlordiazepoxide to alprazolam in our 
elderly patient (case l), because the patient’s age raised 
concerns about the accumulation of a long-acting med- 
ication (Closser, 1991). Although we conservatively 
employed a 25: 1 substitution ratio, our patient ulti- 
mately required a 5O:l substitution ratio after we 
included the “as-needed” doses in our calculation (Ta- 
ble 1). Interestingly, we did not find a significant cor- 
relation between age and substitution ratio (rs = 
-0.43, p = 0.40). 
Our cases were confined to inpatients whose daily 
alprazolam dosage ranged from 2 to 6 mg. We cannot 
recommend this procedure for outpatients at this time, 
nor do we know if our substitution ratios apply to pa- 
tients taking more than 6 mg of alprazolam daily. In 
the substitution and taper method of Smith and Sey- 
mour (1991), a maximum daily dosage of 500 mg of 
phenobarbital (the equivalent of about 420 mg of 
chlordiazepoxide) is recommended, regardless of the 
sedative amount the patient used. 
Our mean follow-up period (2 weeks) was too short 
to observe the full course of withdrawal (2-4 weeks) 
to determine relapse rates and to rule out completely 
a recurrent panic disorder in need of further treatment. 
Nevertheless, withdrawal symptoms do peak, and 
alprazolam-related seizures occur, within 2 weeks of 
discontinuation (American Psychiatric Association, 
1990; Warner et al., 1990). Moreover, our immediate 
outcomes were favorable in contrast to previous re- 
ports of chlordiazepoxide substitution (Albeck, 1987; 
Kantor, 1986). Finally, all inpatients require contin- 
ued monitoring for diagnostic and treatment purposes 
following discharge. Another limitation of our retro- 
spective study was the lack of structured rating scales 
for withdrawal symptoms, which made it difficult to 
distinguish withdrawal symptoms from symptoms of 
a recurrent anxiety disorder. Finally, we did not con- 
duct a controlled, comparison study, so we do not 
know if patients would have done as well or better with 
other withdrawal techniques. However, our main in- 
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terest was in determining the dosing of, and feasibility 
of using, chlordiazepoxide for alprazolam withdrawal. 
In conclusion, we found that inpatients on a chem- 
ical dependency unit successfully tolerated rapid with- 
drawal from alprazolam in doses of 2-6 mg daily when 
chlordiazepoxide was substituted in adequate doses 
and then tapered over l-2 weeks. When the amount of 
chlordiazepoxide was individualized, cross-dependence 
occurred, and seizures were prevented. Chlordiazepox- 
ide has the advantage of familiarity on treatment units 
that regularly use it for alcohol withdrawal. The rapid 
attainment of a drug-free state facilitates entry into 
drug rehabilitation when indicated. Future studies 
should employ a prospective, comparative design with 
structured rating scales and diagnostic assessments, 
and a longer follow-up period. 
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